# Fennec Pharmaceuticals Inc. (FENC) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/FENC
## Company Profile
- Ticker: FENC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 11.83 USD
- Market cap: 346675559.40000004 USD
- Last updated: 2026-08-12
## Business Overview
### Ototoxicity Prevention Company
Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy.
### Pediatric Commercial Foundation
PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through an oncology sales organization and the Fennec HEARS patient-services hub.
### Expansion into Older Patients
Investigator-sponsored studies are evaluating PEDMARK in adolescent, young adult, and adult patients receiving cisplatin for head and neck, testicular, cervical, and other cancers.
## Why The Stock Is Moving

Following the latest company update, “Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update”, FENC closed up 16.8% at $12.78 on Aug 11, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Clinical data from investigator-sponsored PEDMARK studies in additional age groups and tumor types are expected to define potential expansion opportunities.

## Recent News
- 2026-08-11 11:01 EST — [Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provide-7dbed1d0) — Source: Fennec Pharmaceuticals Inc.
- 2026-08-05 11:01 EST — [Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026](https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-august-e5b49ee5) — Source: Fennec Pharmaceuticals Inc.
- 2026-06-15 10:00 EST — [Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)](https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-563-91e85c01) — Source: Fennec Pharmaceuticals Inc.
- 2026-06-10 20:30 EST — [Fennec Announces Results of Annual Meeting](https://biopharmsignal.com/news/FENC/fennec-announces-results-of-annual-meeting-1c0b3630) — Source: Fennec Pharmaceuticals Inc.
- 2026-05-21 22:01 EST — [Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-new-research-supporting-integration-and-use-of-pedmarkr-at-the-2026-asco-annual-meeting) — Source: Fennec Pharmaceuticals Inc.